Targeted delivery of glucocorticoids to macrophages in a mouse model of multiple sclerosis using inorganic-organic hybrid nanoparticles

Journal of Controlled Release

Volumn 245, Issue , 2017, Pages 157-169

  Montes Cobos, Elena ^a   Ring, Sarah ^a   Fischer, Henrike J ^a   Heck, Joachim ^b   Strauß, Judith ^a   Schwaninger, Markus ^c   Reichardt, Sybille D ^a   Feldmann, Claus ^b   Lühder, Fred ^a   Reichardt, Holger M ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Experimental autoimmune encephalomyelitis; Glucocorticoids; Hybrid nanoparticles; Macrophages; Multiple sclerosis; T cells

Indexed keywords

CELLS; CYTOLOGY; DISEASE CONTROL; HORMONES; MACROPHAGES; MAMMALS; NANOPARTICLES; T-CELLS;

BETAMETHASONE PHOSPHATES; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GLUCOCORTICOIDS; HYBRID NANOPARTICLE; INORGANIC-ORGANIC HYBRID; MULTIPLE SCLEROSIS; TARGETED DELIVERY; THERAPEUTIC EFFICACY;

ENDOTHELIAL CELLS;

BETAMETHASONE SODIUM PHOSPHATE; GLUCOCORTICOID; BETAMETHASONE; FLAVINE MONONUCLEOTIDE; GLUCOCORTICOID RECEPTOR; NANOPARTICLE; ZIRCONIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CELL SPECIFICITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; ENDOTHELIUM CELL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; HYBRID; IN VIVO STUDY; MALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; T LYMPHOCYTE; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; C57BL MOUSE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HUMAN; MACROPHAGE; METABOLISM; MONOCYTE; MUTANT MOUSE STRAIN;

ANIMALS; APOPTOSIS; BETAMETHASONE; CELL SURVIVAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FLAVIN MONONUCLEOTIDE; GENE EXPRESSION; GLUCOCORTICOIDS; HUMANS; MACROPHAGES; MALE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MONOCYTES; MULTIPLE SCLEROSIS; NANOPARTICLES; RECEPTORS, GLUCOCORTICOID; T-LYMPHOCYTES; ZIRCONIUM;

EID: 85002716314     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.12.003     Document Type: Article

References (41)

1. [1] El-Gabalawy, H., Guenther, L.C., Bernstein, C.N., Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J. Rheumatol. Suppl. 85 (2010), 2–10.
2. [2] Bruno, V., Battaglia, G., Nicoletti, F., The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases. Neurol. Sci. 31:Suppl. 3 (2011), 283–288.
3. [3] Reichardt, H.M., Gold, R., Lühder, F., Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis. Expert. Rev. Neurother. 6 (2006), 1657–1670.
4. [4] Lühder, F., Reichardt, H.M., Traditional concepts and future avenues of glucocorticoid action in experimental autoimmune encephalomyelitis and multiple sclerosis therapy. Crit. Rev. Immunol. 29 (2009), 255–273.
5. [5] Baschant, U., Tuckermann, J., The role of the glucocorticoid receptor in inflammation and immunity. J. Steroid Biochem. Mol. Biol. 120 (2010), 69–75.
6. [6] Compston, A., Coles, A., Multiple sclerosis. Lancet 359 (2002), 1221–1231.
7. [7] Nylander, A., Hafler, D.A., Multiple sclerosis. J. Clin. Invest. 122 (2012), 1180–1188.
8. [8] Herold, M.J., Reichardt, H.M., Glucocorticoid-induced apoptosis in animal models of multiple sclerosis. Crit. Rev. Immunol. 33 (2013), 183–202.
9. [9] Fischer, H.J., Schweingruber, N., Lühder, F., Reichardt, H.M., The potential role of T cell migration and chemotaxis as targets of glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis. Mol. Cell. Endocrinol. 380 (2013), 99–107.
10. [10] Mosser, D.M., Edwards, J.P., Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8 (2008), 958–969.
11. [11] Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A., Locati, M., The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25 (2004), 677–686.
12. [12] Pasquier, R.A. Du, Pinschewer, D.D., Merkler, D., Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis. CNS Drugs 28 (2014), 535–558.
13. [13] Milligan, N.M., Newcombe, R., Compston, D.A., A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J. Neurol. Neurosurg. Psychiatry 50 (1987), 511–516.
14. [14] Cohen, J.A., Imrey, P.B., Calabresi, P.A., Edwards, K.R., Eickenhorst, T., Felton, W.L. 3rd, Fisher, E., Fox, R.J., Goodman, A.D., Hara-Cleaver, C., Hutton, G.J., Mandell, B.F., Scott, T.F., Zhang, H., Apperson-Hansen, C., Beck, G.J., Houghtaling, P.L., Karafa, M.T., Stadtler, M., Results of the Avonex combination trial (ACT) in relapsing-remitting MS. Neurology 72 (2009), 535–541.
15. [15] Pato-Pato, A., Prieto, J.M., Lema, M., Dapena-Bolano, D., Abella-Corral, J., Pumar, J.M., Cerebral atrophy in multiple sclerosis patients treated periodically with boluses of methylprednisolone. Rev. Neurol. 37 (2003), 501–506.
16. [16] Goodkin, D.E., Kinkel, R.P., Weinstock-Guttman, B., VanderBrug-Medendorp, S., Secic, M., Gogol, D., Perryman, J.E., Uccelli, M.M., Neilley, L., A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology 51 (1998), 239–245.
17. [17] Gold, R., Linington, C., Lassmann, H., Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129 (2006), 1953–1971.
18. [18] Wüst, S., van den Brandt, J., Tischner, D., Kleiman, A., Tuckermann, J.P., Gold, R., Lühder, F., Reichardt, H.M., Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J. Immunol. 180 (2008), 8434–8443.
19. [19] Schweingruber, N., Haine, A., Tiede, K., Karabinskaya, A., van den Brandt, J., Wüst, S., Metselaar, J.M., Gold, R., Tuckermann, J.P., Reichardt, H.M., Lühder, F., Liposomal encapsulation of glucocorticoids alters their mode of action in the treatment of experimental autoimmune encephalomyelitis. J. Immunol. 187 (2011), 4310–4318.
20. [20] Lee, D.H., Rotger, C., Appeldoorn, C.C., Reijerkerk, A., Gladdines, W., Gaillard, P.J., Linker, R.A., Glutathione PEGylated liposomal methylprednisolone (2B3-201) attenuates CNS inflammation and degeneration in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis. J. Neuroimmunol. 274 (2014), 96–101.
21. [21] Schiffelers, R.M., Banciu, M., Metselaar, J.M., Storm, G., Therapeutic application of long-circulating liposomal glucocorticoids in auto-immune diseases and cancer. J. Liposome Res. 16 (2006), 185–194.
22. [22] van den Hoven, J.M., Nemes, R., Metselaar, J.M., Nuijen, B., Beijnen, J.H., Storm, G., Szebeni, J., Complement activation by PEGylated liposomes containing prednisolone. Eur. J. Pharm. Sci. 49 (2013), 265–271.
23. [23] Zhao, C.Y., Fan, T.T., Yang, Y., Wu, M.L., Li, L., Zhou, Z., Jian, Y.L., Zhang, Q., Huang, Y., Preparation, macrophages targeting delivery and anti-inflammatory study of pentapeptide grafted nanostructured lipid carriers. Int. J. Pharm. 450 (2013), 11–20.
24. [24] Ren, K., Dusad, A., Yuan, F., Yuan, H.J., Purdue, P.E., Fehringer, E.V., Garvin, K.L., Goldring, S.R., Wang, D., Macromolecular prodrug of dexamethasone prevents particle-induced peri-implant osteolysis with reduced systemic side effects. J. Control. Release 175 (2014), 1–9.
25. [25] Ren, K., Yuan, H.J., Zhang, Y.J., Wei, X., Wang, D., Macromolecular glucocorticoid prodrug improves the treatment of dextran sulfate sodium-induced mice ulcerative colitis. Clin. Immunol. 160 (2015), 71–81.
26. [26] Heck, J.G., Napp, J., Simonato, S., Mollmer, J., Lange, M., Reichardt, H.M., Staudt, R., Alves, F., Feldmann, C., Multifunctional phosphate-based inorganic-organic hybrid nanoparticles. J. Am. Chem. Soc. 137 (2015), 7329–7336.
27. [27] Kleiman, A., Hübner, S., Rodriguez Parkitna, J.M., Neumann, A., Hofer, S., Weigand, M.A., Bauer, M., Schmid, W., Schütz, G., Libert, C., Reichardt, H.M., Tuckermann, J.P., Glucocorticoid receptor dimerization is required for survival in septic shock via suppression of interleukin-1 in macrophages. FASEB J. 26 (2012), 722–729.
28. [28] Tischner, D., Weishaupt, A., van den Brandt, J., Müller, N., Beyersdorf, N., Ip, C.W., Toyka, K.V., Hünig, T., Gold, R., Kerkau, T., Reichardt, H.M., Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis. Brain 129 (2006), 2635–2647.
29. [29] Schweingruber, N., Fischer, H.J., Fischer, L., van den Brandt, J., Karabinskaya, A., Labi, V., Villunger, A., Kretzschmar, B., Huppke, P., Simons, M., Tuckermann, J.P., Flügel, A., Lühder, F., Reichardt, H.M., Chemokine-mediated redirection of T cells constitutes a critical mechanism of glucocorticoid therapy in autoimmune CNS responses. Acta Neuropathol. 127 (2014), 713–729.
30. [30] Roming, M., Lunsdorf, H., Dittmar, K.E., Feldmann, C., ZrO(HPO(4))(1-x)(FMN)(x): quick and easy synthesis of a nanoscale luminescent biomarker. Angew. Chem. Int. Ed. Eng. 49 (2010), 632–637.
31. [31] Oliveri, R.L., Valentino, P., Russo, C., Sibilia, G., Aguglia, U., Bono, F., Fera, F., Gambardella, A., Zappia, M., Pardatscher, K., Quattrone, A., Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology 50 (1998), 1833–1836.
32. [32] Schmidt, J., Metselaar, J.M., Wauben, M.H., Toyka, K.V., Storm, G., Gold, R., Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 126 (2003), 1895–1904.
33. [33] Chanan-Khan, A., Szebeni, J., Savay, S., Liebes, L., Rafique, N.M., Alving, C.R., Muggia, F.M., Complement activation following first exposure to pegylated liposomal doxorubicin (doxil): possible role in hypersensitivity reactions. Ann. Oncol. 14 (2003), 1430–1437.
34. [34] Szebeni, J., Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 216 (2005), 106–121.
35. [35] Szebeni, J., Baranyi, L., Savay, S., Milosevits, J., Bunger, R., Laverman, P., Metselaar, J.M., Storm, G., Chanan-Khan, A., Liebes, L., Muggia, F.M., Cohen, R., Barenholz, Y., Alving, C.R., Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies. J. Liposome Res. 12 (2002), 165–172.
36. [36] Szebeni, J., Storm, G., Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs. Biochem. Biophys. Res. Commun. 468 (2015), 490–497.
37. [37] Weissleder, R., Nahrendorf, M., Pittet, M.J., Imaging macrophages with nanoparticles. Nat. Mater. 13 (2014), 125–138.
38. [38] Demir, E., Burgucu, D., Turna, F., Aksakal, S., Kaya, B., Determination of TiO2, ZrO2, and Al2O3 nanoparticles on genotoxic responses in human peripheral blood lymphocytes and cultured embyronic kidney cells. J. Toxicol. Environ. Health A 76 (2013), 990–1002.
39. [39] Karunakaran, G., Suriyaprabha, R., Manivasakan, P., Yuvakkumar, R., Rajendran, V., Kannan, N., Screening of in vitro cytotoxicity, antioxidant potential and bioactivity of nano- and micro-ZrO2 and -TiO2 particles. Ecotoxicol. Environ. Saf. 93 (2013), 191–197.
40. [40] Saxena, V., Diaz, A., Clearfield, A., Batteas, J.D., Hussain, M.D., Zirconium phosphate nanoplatelets: a biocompatible nanomaterial for drug delivery to cancer. Nanoscale 5 (2013), 2328–2336.
41. [41] Obando-Pereda, G.A., Fischer, L., Stach-Machado, D.R., Titanium and zirconia particle-induced pro-inflammatory gene expression in cultured macrophages and osteolysis, inflammatory hyperalgesia and edema in vivo. Life Sci. 97 (2014), 96–106.